What does thymosin alpha-1 cost in each channel?
Prices in US dollars at the verification date. Ranges are published list or program prices where a primary source exists; notes say when a figure is a typical market range instead.
| Channel | Price (USD) | Notes |
|---|---|---|
| With insurance | Not published | Not covered. Medicare Part D and commercial pharmacy benefits cover FDA approved drugs for accepted indications; compounded or unapproved peptides are paid in cash. [3] |
| Compounded pharmacy | Not published | No lawful compounded price. Thymosin alpha-1 was placed on 503A Category 2 in 2023 and the nomination was later withdrawn, so it has no active nomination and is not on the bulks list. Products sold as research chemicals for human use are unapproved drugs and are unverified for identity or purity. [1] [2] [4] |
Why is there no price for thymosin alpha-1?
FDA has found an online seller offering thymosin alpha-1 anyway. [5]
Clinics and telehealth programs may quote you a cash price for thymosin alpha-1. PeptideAgent lists none, for two reasons. There is no thymosin alpha-1 product to price: none is FDA approved, and a pharmacy has no federal basis to compound it. [1] [2] A quoted price is for a product FDA has not checked for safety, effectiveness, or quality, so it is not the price of a reviewed drug. [6]
If you're going ahead anyway: the checklist on the thymosin alpha-1 page. These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound thymosin alpha-1, with or without a prescription. [2]
- Check the pharmacy's license
- What a legitimate prescription and consult look like
- Why this is safer than a research-use-only product
- Questions to ask the pharmacy, the telehealth company, the prescriber, and anyone offering it
What is the list price of thymosin alpha-1?
There is no US list price. It is approved abroad as Zadaxin (thymalfasin) and sold by prescription in those countries, but it is not FDA approved and personal importation is not a licensed US channel.
Does insurance cover thymosin alpha-1?
Not covered; there is no approved or lawfully compounded US product to cover.
What changes the price?
- Absence of any lawful compounding basis since the 2023 Category 2 placement and later withdrawal
Frequently asked questions
How much does thymosin alpha-1 cost without insurance?
No lawful compounded price. Thymosin alpha-1 was placed on 503A Category 2 in 2023 and the nomination was later withdrawn, so it has no active nomination and is not on the bulks list. Products sold as research chemicals for human use are unapproved drugs and are unverified for identity or purity. [1] [2] [4]
Does insurance cover thymosin alpha-1?
Not covered; there is no approved or lawfully compounded US product to cover. [3]
What is the list price of thymosin alpha-1?
There is no US list price. It is approved abroad as Zadaxin (thymalfasin) and sold by prescription in those countries, but it is not FDA approved and personal importation is not a licensed US channel.
Related pages
From the blog
- Thymosin alpha-1 benefits and side effects: the evidence
What randomized trials of thymosin alpha-1 showed in hepatitis B, sepsis, COVID-19, and vaccine response, which side effects they recorded, and where wellness claims outrun the data.
- Thymosin alpha-1 access: approved abroad, not in the US
Thymosin alpha-1 is approved as Zadaxin in more than 30 countries but has never been FDA approved, and it is not on the 503A bulks list. What that means for access, forms, and thymalin.
Sources
- [1]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list and withdrawn nominations, content current as of April 22, 2026)FDA
- [2]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA
- [3]Medicare.gov: prescription drug coverage (Part D and outpatient drugs)
- [4]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
- [5]FDA warning letter 612014, December 7, 2020, to an online peptide seller (FDA warning letters database)FDA, 2020
- [6]FDA: Compounding and the FDA, questions and answersFDA